A vial arrives at the stores bench, is checked against its paperwork and signed into the inventory system. Behind that routine action sits a detail that is easy to overlook and awkward to correct later: the declared excipients. The current FAQs from Research Sciences state that its peptides contain trace amounts of mannitol, described as an excipient that helps the vial not look empty, supports stability during lyophilisation, aids solubility and offers protection in storage. Capturing that fact at booking-in keeps the batch record, the CoA file and the laboratory’s own worksheets aligned. None of these materials are for human or veterinary use; they are supplied strictly for controlled laboratory and analytical research.
Why a Lyophilised Research Vial Declares Mannitol at All
Every freeze-dried research vial contains two categories of material: the compound under study and the formulation components that make the powder practical to manufacture, fill, store and handle. Mannitol belongs firmly to the second category. It is a declared excipient — a component listed on the documentation so that a laboratory knows precisely what sits alongside the peptide in the vial, rather than discovering it halfway through an assay.
During a freeze-drying cycle, a bulking agent gives the lyophilised cake its structure. A very small quantity of peptide on its own would leave an almost invisible plug at the base of the vial: difficult to see, difficult to resuspend consistently and easy to lose during weighing or aliquoting. Mannitol forms a uniform crystalline matrix that supports a reproducible cycle and produces a visible, well-formed cake. This is why the excipient appears in the declared composition and why a stores entry that records only the peptide name and mass is incomplete.
The practical consequence for the researcher is a distinction between total fill mass and peptide mass. A declared presentation such as 5mg or 10mg refers to the compound, not to the entire powder in the vial. When planning an in-vitro assay, concentration should be calculated from the declared peptide content, with the excipient treated as part of the formulation rather than as active material. Where identity and purity are concerned, the figure that matters is the one printed for that specific batch on its Certificate of Analysis. The homepage’s published “≥99% Verified Purity” line is the shop’s marketing wording and should be reconfirmed both on the live site and against the batch CoA before any record is finalised.
It bears repeating in the stores record itself: materials of this kind are not medicines, medical devices, injectables, treatments or food supplements under UK law, and they are not for human or veterinary use. Any inventory note should carry that status forward to whoever next opens the vial.
The Booking-In Workflow: From Label Reference to Stores Entry
Checking the vial before it is signed in
Booking in begins before the vial is opened. Lyophilised material should be allowed to reach room temperature in its sealed vial, and opening should take place in a clean, controlled environment as part of a documented laboratory workflow. Vial labels use a reference format that combines the SKU code with an expiry date — for example BPC10-03/27 — and that reference links to the corresponding CoA. It is the single most useful string of characters in the whole process, because it ties the physical item to its documentation.
Fields a stores entry should capture
A defensible booking-in record typically includes: product name and catalogue code; the full label reference including expiry; fill quantity; declared excipients, including mannitol; the storage condition stated for that item; quantity received; storage location; the date booked in; and the initials of the person completing the entry. The excipient field is not decorative — it explains the appearance and mass of the cake, and it answers the most common audit question about why the powder weighs more than the declared peptide content.
Internal Test References and packaging variation
The FAQs note that restocked products may carry the same Internal Test Reference (ITR) as earlier stock. An ITR links to associated sample testing reports; it does not confirm that separate deliveries came from the same production lot or received separate independent testing. Vial cap colours and other packaging details may also vary between deliveries, and cap colour is not an indicator of identity, analytical quality or manufacturing origin. Stores entries should therefore record the label reference and ITR as printed, without inferring more than the documentation supports.
Fulfilment wording deserves the same care. The FAQs describe orders dispatched the next working day via Royal Mail Tracked 24, which usually delivers the following working day — a carrier estimate, not a guarantee — while headline lines such as “24hr UK Delivery” and “3,000+ UK Orders” are published marketing figures at the time of writing and should be reconfirmed on the live site. Where a stores team needs to re-check the declared form, presentation or storage guidance before signing a batch in, the current catalogue listings on Peptides uk set out those details for each research-use-only item, and the accompanying CoA remains the authoritative document for the batch in hand.
Documentation, COSHH and the Questions Stores Teams Actually Ask
Matching paperwork to the physical batch
Before a batch is released into general laboratory stock, the CoA should be opened, read and filed against the label reference. Research Sciences describes an expanded testing framework covering purity and identity by HPLC alongside heavy-metals and endotoxin screening, with CoAs linked to supported products; the homepage also lists “CoAs Janoshik Analytical Reports”. Treat all of this as the shop’s published description, and verify the actual document that accompanies the specific batch rather than relying on a remembered headline. If a document is missing or a reference does not match, hold the vial in quarantine and quote the label reference when contacting support, which the site describes as available seven days a week.
COSHH and physical handling
Lyophilised powders are handled under the purchaser’s own risk assessment and COSHH arrangements, which remain the buyer’s responsibility. In practice, that means weighing and dispensing in an appropriate enclosure, controlling dust, using suitable personal protective equipment, and defining who may open the vial and where. Mannitol’s presence in the declared composition should appear in the substance inventory attached to that assessment, since it is a named component of the material being handled. Storage follows the handling guide: lyophilised peptides at −20°C or below, sealed with desiccant, protected from moisture, heat and light, and out of repeated freeze–thaw cycles.
Reconstitution questions, kept in the laboratory
Where a protocol calls for reconstitution, the discussion belongs entirely within an in-vitro workflow: choosing a diluent volume that yields the working concentration the assay requires, noting that reconstitution solutions are supplied separately, and recording the resulting concentration on the worksheet. The free reconstitution calculator described on the product pages and in the FAQs is a laboratory aid only and must never be used for human or veterinary dosing. Reconstituted material is less stable and is stored at 2–8°C for short-term laboratory use, per the site’s guidance.
Finally, stores teams should note the published returns position: no returns once dispatched, with refunds only for damage, incorrect supply or quality issues as set out in the Refunds & Returns Policy. Each entry should close with the reminder that the material is for research use only, not for human or veterinary use, and is not to be administered, ingested or applied clinically by anyone at any stage of the workflow.
